Literature DB >> 3396364

Organization, review, and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967.

.   

Abstract

Cooperative studies have been designed as a means of obtaining definite answers to significant questions not readily answerable by other means. Such studies should be initiated only if an important problem needs a rapid solution, the study is feasible and likely to answer the problem, and strong and stable leadership are assured. Protocol and operating procedures must be kept as simple as possible. Control of performance at all levels must be built into the structure. Organizational components should include: (a) a Policy or Advisory Board, (b) an Executive or Steering Committee, (c) a Coordinating Center, and (d) data-contributing participants. All of these components must interrelate with each other and with National Heart Institute staff and, through the staff, with scientific review groups and the National Advisory Heart Council. A chart of organization is shown in Figure 1. The most important position is that of Chairman of the Steering Committee; the key component is the Coordinating Center. The performance of the Coordinating Center is continuously dependent on full-time, highly disciplined leadership that must continually maintain active lines of communication with all participants. Failure to achieve this seriously undermines the effectiveness and value of the study. Participation in a cooperative study, with required adherence to a common protocol, can divert some scientists from original research. Conversely, others may be introduced to research methodology through participation. The benefits that can be achieved only through cooperative efforts must be carefully balanced against any adverse effects of encouraging large numbers of investigators to work in cooperative studies. Exceedingly complex value judgments are required of reviewers, who must constantly keep in mind the need to maintain a reasonable balance within the funds appropriated for research. Their deliberations should include an evaluation of technical approaches, organization, biostatistical aspects, duration, and budget. Comprehensive annual progress reports and recall of former consultants could facilitate continuity of review. Free communication between the National Advisory Heart Council and the initial review groups is essential to enhance working relationships and understanding between these two levels of review. Approval of a preliminary study should carry with it a degree of commitment to a major study if feasibility can be demonstrated and adequate methodology developed.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3396364     DOI: 10.1016/0197-2456(88)90034-7

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  17 in total

1.  Methods and management: NIH administrators, federal oversight, and the Framingham Heart Study.

Authors:  Sejal S Patel
Journal:  Bull Hist Med       Date:  2012       Impact factor: 1.314

2.  Experiences and challenges in data monitoring for clinical trials within an international tropical disease research network.

Authors:  M Chen-Mok; M J VanRaden; E S Higgs; R Dominik
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

Review 3.  A primer on data safety monitoring boards: mission, methods, and controversies.

Authors:  Lisa K Hicks; Andreas Laupacis; Arthur S Slutsky
Journal:  Intensive Care Med       Date:  2007-07-28       Impact factor: 17.440

4.  Independent data monitoring committees: preparing a path for the future.

Authors:  Connie N Hess; Matthew T Roe; C Michael Gibson; Robert J Temple; Michael J Pencina; Deborah A Zarin; Kevin J Anstrom; John H Alexander; Rachel E Sherman; Fred T Fiedorek; Kenneth W Mahaffey; Kerry L Lee; Shein-Chung Chow; Paul W Armstrong; Robert M Califf
Journal:  Am Heart J       Date:  2014-05-15       Impact factor: 4.749

Review 5.  Independent data monitoring committees: an update and overview.

Authors:  Oliver Sartor; Susan Halabi
Journal:  Urol Oncol       Date:  2015-01-24       Impact factor: 3.498

6.  Data monitoring committees: Promoting best practices to address emerging challenges.

Authors:  Thomas R Fleming; David L DeMets; Matthew T Roe; Janet Wittes; Karim A Calis; Amit N Vora; Alan Meisel; Raymond P Bain; Marvin A Konstam; Michael J Pencina; David J Gordon; Kenneth W Mahaffey; Charles H Hennekens; James D Neaton; Gail D Pearson; Tomas Lg Andersson; Marc A Pfeffer; Susan S Ellenberg
Journal:  Clin Trials       Date:  2017-02-01       Impact factor: 2.486

Review 7.  Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.

Authors:  Jennifer S Gewandter; Rachel A Kitt; Matthew R Hunsinger; Joseph Poku; Jacqueline Lozano; Jenna Chaudari; Scott Evans; Robert A Gross; Michael P McDermott; Michael C Rowbotham; Dennis C Turk; Robert H Dworkin
Journal:  J Clin Epidemiol       Date:  2017-01-23       Impact factor: 6.437

8.  Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods.

Authors:  Jean-Sébastien Hulot; Michel Cucherat; Andrew Charlesworth; Dirk J Van Veldhuisen; Jean-Christophe Corvol; Alain Mallet; Jean-Pierre Boissel; John Hampton; Philippe Lechat
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

Review 9.  Pragmatic Clinical Trials in CKD: Opportunities and Challenges.

Authors:  Ian H de Boer; Csaba P Kovesdy; Sankar D Navaneethan; Carmen A Peralta; Delphine S Tuot; Miguel A Vazquez; Deidra C Crews
Journal:  J Am Soc Nephrol       Date:  2016-06-09       Impact factor: 10.121

10.  A centralized informatics infrastructure for the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Jeng-Jong Pan; Meredith Nahm; Paul Wakim; Carol Cushing; Lori Poole; Betty Tai; Carl F Pieper
Journal:  Clin Trials       Date:  2009-02       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.